Roche's 'blowout' cancer launches help fuel 10% profits hike - FiercePharma#ixzz2hhLD...
`
`Page 1 of 3
`
`FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`EMAIL ADDRESS
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Don't fire me, Sanofi CEO tells board, amid tussle
`over strategy
`UPDATED: Looming trouble in Sanofi's diabetes biz
`turns up the heat on CEO
`Pharma's top 10 M&A deals of 2014's first half
`Sanofi canned its outspoken CEO. Will the board go
`French with a replacement?
`Pfizer's Q3 beats, but flat sales mean CEO Read
`needs a big move
`
`THE LIBRARY: EBOOK
`Special Report | The Changing Landscape of
`Phase IV Research
`
`| PUBLISHED: SEPTEMBER 29, 2014 |
`SPONSORED BY: COVANCE
`
`Topics: Financials
`Roche's 'blowout' cancer launches help fuel 10%
`profits hike
`July 25, 2013 | By Tracy Staton
`
`Fueled by a "blowout" launch of its new breast-cancer drug Kadcyla, Roche
`($RHHBY) posted a 10% hike in profits for the first half of the year, on sales that
`topped analyst estimates at 7.58 billion Swiss francs, or about $8 billion. The
`rest of Roche's cancer portfolio delivered, too, with top-selling Rituxan bringing
`home 1.7 billion francs.
`
`Approved by the FDA in February, Kadcyla brought in
`65 million francs, or about $69.5 million, for the second
`quarter, Kepler Cheuvreux analyst Fabian Wenner told
`Bloomberg. For the entire half-year--the figures Roche
`reported today--Kadcyla garnered global sales of 83
`million francs. Another new breast cancer treatment,
`Perjeta, approved by the FDA last November,
`accounted for 108 million francs.
`
`"It was a blowout result," Wenner told the news service
`of Kadcyla's sales.
`
`Roche CEO Severin
`Schwan
`
`Webinar: Leveraging Metabolite Biomarkers for Clinical Trials
`
`DATE: THURSDAY, OCTOBER 30, 11 AM ET / 8 AM PT
`This webinar will introduce a robust, highly sensitive biomarker development program
`that leverages the revolutionary metabolomics discovery platform and expands the menu of
`compounds that can be measured routinely and reliably. Register Now!
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`Roche needs new products to kick in as it prepares for biosimilar competition to
`its gold-standard older drugs, including Rituxan, a treatment for blood cancers
`and autoimmune disease, and Herceptin, the breast cancer therapy, which
`brought in 1.55 billion francs for the period. That's 3.25 billion francs at risk, or
`about $3.5 billion. Analysts are expecting biosimilars to hit in the U.S. as soon as
`2015, but Roche now says it sees Rituxan biosims waiting till 2016.
`
`Roche has been pushing beyond cancer, with R&D efforts in asthma, diabetes
`and Alzheimer's disease, among others. Its success has been limited so far;
`pharma chief Daniel O'Day noted today during the earnings call that the
`
`SHARE
`
`17
`
`Tweet
`
`5 S
`
`Share
`hare
`
`0
`
`LikeLike
`
`3
`
`TOOLS
`
`Comment
`
`Print
`
`Contact
`Author
`
`Reprint
`
`http://www.fiercepharma.com/story/roches-blowout-cancer-launches-help-fuel-10-profits...
`
`10/29/2014
`
`IMMUNOGEN 2245, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Roche's 'blowout' cancer launches help fuel 10% profits hike - FiercePharma#ixzz2hhLD...
`
`Page 2 of 3
`
`company may abandon heart and metabolic diseases completely. "We are still
`deciding," he said (as quoted by Bloomberg).
`
`What else can Roche do to prep for competition? Deals, of course. The
`company is said to be eyeing a deal for Alexion Pharmaceuticals ($ALXN), the
`U.S.-based rare-disease specialist that reaps billions from small patient
`populations. Its Soliris treatment for two rare diseases brought in $1.13 billion
`last year. Though Roche CEO Severin Schwan wouldn't comment on a potential
`Alexion deal, he did say the company is eyeing bolt-on buyouts.
`
`"As far as our overall innovation strategy is concerned there is no change,"
`Schwan said (as quoted by Reuters). "It has always been our strategy to have
`internal and external innovation. ... [W]e will continue to focus on bolt-on
`acquisitions."
`
`- see the Roche earnings release
`- get more from Bloomberg
`- check out the Reuters news
`- here's more on diagnostics sales from FierceMedicalDevices
`
`Special Reports: The Roche billionaires - Fierce's 10 top biotech billionaires |
`Top 10 Best-selling Cancer Drugs | Top Pharma Companies by 2012 Revenues
`
`Related Articles:
`Roche casts its net (again) for the perfect chairman
`Roche may want Alexion, but is the price right?
`With nod, Roche's Kadcyla should quickly become blockbuster
`FDA approves Roche's pricey new Herceptin partner, Perjeta
`No stock buybacks for Roche. Let's make a $7B deal instead
`
`Sign up for our free newsletter
`
`EMAIL ADDRESS
`
`Filed Under Kadcyla, Roche
`
`COMMENTS
`
`Industry spending on post-
`authorization studies belies the rapid changes
`occurring in Phase IV research, driven by an
`the demand for evidence of safety and
`effectiveness. Download this Special Report to
`learn how Phase IV research continues to
`transform.
`
`MORE ITEMS
`
`LATEST COMMENTARY
`
`Cancer survivor's petition pleads with Roche for
`lower Kadcyla price
`Merck hops onto HBCU network to step up its brand
`in the African-American community
`Sunshine fact: $3.5B + 546,000 docs equals one
`unwieldy database
`Copay coupons get the Inspector General treatment
`First-to-market launch? Bonus--but double bonus if
`you're Big Pharma
`
`EVENTS
`
`Human Abuse Liability & Abuse-Deterrent
`Formulations Summit
`Nov 17-18 — Silver Spring, MD — Sponsored
`by: ExL Pharma
`
`3rd Content Marketing for Life Sciences
`December 4-5 — Philadelphia, PA —
`Sponsored by: ExL Pharma
`
`Clinical Performance Metrics &
`Benchmarking
`December 12-13 — Philadelphia, PA
`MORE EVENTS
`
`http://www.fiercepharma.com/story/roches-blowout-cancer-launches-help-fuel-10-profits...
`
`10/29/2014
`
`IMMUNOGEN 2245, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Roche's 'blowout' cancer launches help fuel 10% profits hike - FiercePharma#ixzz2hhLD...
`
`Page 3 of 3
`
`0 Comments
`
`PRESS RELEASES
`Abbott Expands Its Medical Device Business wi
`Catheter-Based Electrophysiology Market
`CSL Behring Signs Strategic Development Agre
`Injections To Market Novel New Drug Delivery D
`pSivida Corp (PSDV) Pockets $25 Million Milesto
`ZOLL Announces Acquisition of the Assets of Im
`Inc.
`Inogen (INGN) Announces Launch Of Proposed
`Offering By Selling Stockholders
`More Press Releases
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`Orphan drug prices on non-orphan
`meds? Gilead, this means you, …
`•
`
`A
`
` — Yeah but Harvoni is a cure,
`orphan drugs are not. I think you're more
`worried aboutyour own profits …
`
`Payers hit back at Gilead for $94,500
`price tag on brand-new hep C …
`•
`
`A
`
` — OUTRAGEOUS!
`
`GSK dealmaking spawns management
`shake-up, putting …
`•
`
` — I heard that heads were rolling
`at GSK . . .
`
`India's NPPA fines Novartis $49M as
`price cap battles rage on
`•
` — Good job NPPA , put these
`scums in line
`
`A publication of
`
`FiercePharma is the pharma
`industry's daily monitor, with
`a special focus on
`pharmaceutical company
`news and the market
`development of FDA
`approved products. Join
`150,000+ pharma industry
`leaders who get
`FiercePharma via daily
`email. Click here to get your
`free weekly email briefing
`today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless:Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMedicalImaging
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDiagnostics
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceEnterpriseCommunicatio
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`FierceSmartGrid
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscribe Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2014 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.
`
`http://www.fiercepharma.com/story/roches-blowout-cancer-launches-help-fuel-10-profits...
`
`10/29/2014
`
`IMMUNOGEN 2245, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`